LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

Fate Therapeutics Inc

Închisă

SectorSănătate

0.96 -4.95

Rezumat

Modificarea prețului

24h

Curent

Minim

0.95

Maxim

0.97

Indicatori cheie

By Trading Economics

Venit

3.6M

-34M

Vânzări

278K

1.9M

Marjă de profit

-1,786.576

Angajați

181

EBITDA

979K

-37M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+312.75% upside

Dividende

By Dow Jones

Următoarele câștiguri

10 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

4.1M

111M

Deschiderea anterioară

5.91

Închiderea anterioară

0.96

Sentimentul știrilor

By Acuity

50%

50%

175 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Fate Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 sept. 2025, 22:41 UTC

Principalele dinamici ale pieței

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 sept. 2025, 16:04 UTC

Principalele dinamici ale pieței

Upexi Shares Climb on Solana Gains

12 sept. 2025, 15:03 UTC

Principalele dinamici ale pieței

Allied Gaming & Entertainment Shares Surge Following Crypto Investments

12 sept. 2025, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

12 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 sept. 2025, 20:09 UTC

Câștiguri

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 sept. 2025, 19:23 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept. 2025, 19:16 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept. 2025, 19:03 UTC

Market Talk

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 sept. 2025, 18:59 UTC

Market Talk

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 sept. 2025, 18:38 UTC

Market Talk
Câștiguri

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 sept. 2025, 18:33 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 sept. 2025, 18:22 UTC

Market Talk

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 sept. 2025, 16:56 UTC

Market Talk

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 sept. 2025, 16:22 UTC

Câștiguri

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 sept. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 sept. 2025, 16:19 UTC

Achiziții, Fuziuni, Preluări

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

12 sept. 2025, 16:11 UTC

Câștiguri

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 sept. 2025, 15:37 UTC

Market Talk

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 sept. 2025, 15:22 UTC

Market Talk

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 sept. 2025, 15:07 UTC

Achiziții, Fuziuni, Preluări

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sept. 2025, 14:34 UTC

Market Talk

Russia Sanctions Put Bid Back in Oil -- Market Talk

12 sept. 2025, 14:10 UTC

Market Talk

Inflation Report Unlikely to Dissuade Canada From Rate Cut -- Market Talk

12 sept. 2025, 13:58 UTC

Market Talk

Dollar Could Rise if Fed Sounds Cautious on Rate Cuts -- Market Talk

12 sept. 2025, 13:58 UTC

Achiziții, Fuziuni, Preluări

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Super Micro, Adobe, Microsoft, Figure Technology, and More -- Barrons.com

12 sept. 2025, 13:57 UTC

Câștiguri

AbbVie Stock Hit a Record on 'Big Win' for Blockbuster Drug. The Case for Buying In. -- Barrons.com

12 sept. 2025, 13:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 sept. 2025, 13:56 UTC

Market Talk

Canadian Dollar Faces Further Weakness Vs Non-U.S. Dollar Currencies -- Market Talk

12 sept. 2025, 13:54 UTC

Market Talk

U.S. Natural Gas Recovers Ground -- Market Talk

Comparație

Modificare preț

Fate Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

312.75% sus

Prognoză pe 12 luni

Medie 4.21 USD  312.75%

Maxim 7 USD

Minim 2 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruFate Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

9 ratings

3

Cumpărare

6

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.9101 / 1.14Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Very Strong Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

175 / 371 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
help-icon Live chat